Low-dose methotrexate has not been shown to cause cancer in humans, and the evidence overall leans against it being a carcinogen at the doses used for rheumatoid arthritis, psoriasis, and Crohn's disease. The drug is not classified as a human carcinogen by the International Agency for Research on Cancer. Some large cohort studies even report modestly lower risks of certain cancers, particularly colorectal and breast cancer, among long-term users. The genuine concerns are different ones: a rare but real link to lymphoproliferative disorders that usually regress when the drug stops, and a possible small increase in non-melanoma skin cancer and melanoma. In plain terms: the cancer question is mostly a "no," but with two specific exceptions worth understanding.
The mechanism: why a folate antagonist is not automatically a carcinogen
Methotrexate works by inhibiting dihydrofolate reductase, the enzyme that recycles folate into its active form. That starves rapidly dividing cells of the building blocks for DNA synthesis. At the low doses used in inflammatory disease (typically 7.5 to 25 mg once weekly), the drug's dominant effect is not cell killing at all.
Low-dose methotrexate raises extracellular adenosine, which dampens inflammation through adenosine receptors on immune cells. This anti-inflammatory action is why it works in rheumatoid arthritis and psoriasis. It is also mechanistically different from the drug's role in high-dose cancer chemotherapy, where doses run 100 to 1,000 times higher and the intent is direct cytotoxic cell death.
This distinction matters for the carcinogenicity question. A drug that suppresses inflammation and immune activation is mechanistically more likely to reduce, not increase, some inflammation-driven cancers. The trade-off is immunosuppression, which theoretically raises risk for cancers driven by impaired immune surveillance, particularly lymphomas and skin cancers. Both directions are biologically plausible, which is why the question requires population data rather than mechanistic reasoning alone.
In plain terms: low-dose methotrexate calms the immune system rather than poisoning it, and that cuts both ways for cancer risk.
What the large cohort data show
The strongest human evidence comes from long-running cohorts of rheumatoid arthritis patients, a group with elevated baseline cancer risk from the disease itself.
| Cancer type | Direction of association | Approximate magnitude | Evidence quality |
|---|---|---|---|
| Colorectal cancer | Lower risk | 20 to 40 percent reduction | Moderate, consistent across cohorts |
| Breast cancer | Lower or neutral risk | 10 to 30 percent reduction in some studies | Moderate |
| Non-melanoma skin cancer | Possibly higher risk | Roughly 1.2 to 1.5-fold increase | Weak to moderate |
| Melanoma | Possibly higher risk | Small increase in some cohorts | Weak |
| Lymphoma | Neutral in most cohorts | No consistent increase | Moderate |
| Lung cancer | Neutral | No consistent increase | Moderate |
A widely cited analysis of Swedish and Danish rheumatoid arthritis registries found no overall increase in cancer incidence among methotrexate users compared with the general population after accounting for disease severity. Some cohorts, including work published in Arthritis & Rheumatology in the 2010s, reported lower colorectal cancer rates among long-term users.
The skin cancer signal is the most persistent. Several cohorts report modest elevations in squamous cell carcinoma and basal cell carcinoma among long-term users, particularly those with psoriasis who have prior ultraviolet exposure. The effect size is small and confounded by sun exposure, prior phototherapy, and disease severity.
The melanoma data are weaker and inconsistent. Some meta-analyses suggest a small increase; others find nothing after adjustment. The honest position is that this remains an open question with a signal too weak to draw firm conclusions.
The rare lymphoproliferative exception
The clearest cancer-related concern with low-dose methotrexate is a group of lymphoproliferative disorders, sometimes called "other iatrogenic immunodeficiency-associated lymphoproliferative disorders." These are not typical lymphomas.
They typically appear after years of therapy, often in patients with rheumatoid arthritis, and frequently involve Epstein-Barr virus. The key feature is that a substantial proportion regress completely when methotrexate is withdrawn, a pattern rarely seen in spontaneous lymphoma. Reported regression rates range from roughly 40 to 60 percent in case series, which is why withdrawal is the first step in management.
The absolute risk is low. Estimates from rheumatology cohorts place it at roughly 1 in 1,000 to 1 in 5,000 patient-years of methotrexate exposure, though case definitions vary. For context, a patient on methotrexate for 10 years might face a cumulative risk in the low single digits per thousand.
This is the mechanism most worth knowing: methotrexate-induced immunosuppression can allow EBV-driven B-cell proliferation, and removing the drug restores immune control in many cases. It is not a classical mutagenic pathway.
Timeline: when concerns typically emerge
| Time on methotrexate | Typical concern | What to watch |
|---|---|---|
| 0 to 3 months | No cancer concern | Monitoring for toxicity, not malignancy |
| 1 to 5 years | Skin cancer surveillance begins | Annual skin exams, especially with prior UV exposure |
| 5 to 10 years | Lymphoproliferative disorders reported | Unexplained lymph node swelling, night sweats, weight loss |
| 10 to 15 years | Cumulative skin cancer risk accumulates | Continued dermatologic surveillance |
| Any point | EBV-associated lymphoproliferation | New persistent lymphadenopathy warrants evaluation |
| Post-withdrawal | Regression of lymphoproliferative lesions | Reassess within weeks to months of stopping |
Most lymphoproliferative cases appear after several years of therapy, though they can occur earlier. Skin cancer risk accrues with cumulative exposure and prior ultraviolet damage.
Common misconceptions, corrected
The most persistent misconception is that because methotrexate is a chemotherapy drug, low doses must carry chemotherapy's carcinogenic profile. This conflates dose, mechanism, and context. At chemotherapy doses, the drug is cytotoxic and immunosuppressive in ways that low doses are not. The relevant comparison is other immunosuppressants, not chemotherapy.
A second misconception is that any cancer diagnosis during methotrexate therapy implies causation. Rheumatoid arthritis itself carries elevated risks of lymphoma and lung cancer independent of treatment, and psoriasis carries elevated risks of skin cancer and lymphoma. Confounding by indication is the central difficulty in this literature.
A third misconception is that skin cancer risk means the drug should be avoided. The dermatologic data suggest surveillance, not avoidance. Annual skin examinations and sun protection are proportionate responses. For most patients, the cardiovascular and joint-destruction benefits of methotrexate outweigh a small absolute skin cancer risk.
What to actually do
If you are on low-dose methotrexate, these actions address the real risks:
- Get an annual full-body skin examination, especially if you have psoriasis, fair skin, or significant sun exposure history.
- Report any new persistent lymph node swelling, unexplained fever, night sweats, or weight loss to your rheumatologist or dermatologist promptly.
- Take folic acid supplementation as prescribed; it reduces mucosal and hematologic toxicity and does not appear to reduce efficacy.
- Keep all monitoring appointments for blood counts and liver enzymes, which detect toxicity rather than cancer.
- Do not stop methotrexate on your own if a lymphoproliferative concern arises; coordinate with your specialist, because withdrawal itself is part of the diagnostic and therapeutic strategy.
Red flags that warrant urgent evaluation:
- A painless, enlarging lymph node persisting more than four weeks
- New B symptoms: fever, drenching night sweats, unintended weight loss
- A skin lesion that is new, changing, or non-healing
- Unexplained fatigue with abnormal blood counts
How strong is the evidence, really?
The cancer question for low-dose methotrexate is limited by the same problems that affect all long-term drug safety research. Rheumatoid arthritis and psoriasis are themselves cancer-associated conditions, so separating drug effects from disease effects is difficult. Cohort studies rely on registries with variable cancer ascertainment. Randomized trials are too short to detect malignancies that take a decade to emerge.
The colorectal and breast cancer findings are consistent enough to be reassuring, but they may partly reflect healthier-user effects or better cancer screening among monitored patients. The skin cancer signal is biologically plausible and persistent but small and confounded by ultraviolet exposure. The lymphoproliferative signal is real, well-characterized, and mechanistically explained by immunosuppression and EBV reactivation.
What the evidence does not support is a general carcinogenicity claim. The International Agency for Research on Cancer does not list methotrexate as a known human carcinogen, and the American College of Rheumatology's 2021 guideline on rheumatoid arthritis treatment treats malignancy risk as a monitoring consideration rather than a contraindication for most patients. The 2021 guideline does flag caution in patients with prior malignancy or significant risk factors, recommending individualized discussion.
The practical reconciliation is this: the lymphoproliferative risk is real but rare and often reversible, while the skin cancer signal is small enough that surveillance is the appropriate response, and the colorectal and breast signals lean protective. No single number captures the balance, and any claim of a large cancer effect in either direction overstates the data.
For a patient weighing methotrexate, the honest summary is that the drug has a decades-long safety record with no established general carcinogenicity, two specific and manageable concerns, and a risk-benefit profile that most rheumatology and dermatology guidelines still favor for moderate to severe inflammatory disease.